The life science industry has made major strides in developing and providing patient-centered healthcare solutions. Yet, even with all of the regulatory incentives and medical advancements over the years, there still exist a number of vulnerable populations in need of treatment development.

Vulnerable populations affected by neglected tropical diseases and rare (pediatric) diseases are some of the most at-risk patients, and there is an increasing need for the research and development of medical countermeasures in today’s world. These diseases can pose a public health risk and place a significant social and economic burden on global communities. However, since treatments for the affected patient populations typically lack commercial viability, and face many pricing and access challenges, there is a lack of investment in the development and supply of affordable treatments for these neglected diseases.

A successful neglected tropical disease (NTD) program utilizes private and public resources through strong multi-sector partnerships across the biomedical landscape. Finding the balance between social equity and business goals is key for global health partners to provide access to treatments and other resources. ExL’s NTDs Forum will function as a platform for participants to unpack the benefits and logistical hurdles of multi-sector partnerships in the NTD space. Attendees will explore the impact that multi-sector partnerships have on related policies and regulatory strategies to overcome market access challenges associated with neglected tropical disease treatments.

This forum will provide attendees with the opportunity to attend sessions from the following unique conferences:

Priority Review Voucher

Learn More

Drug Repurposing

Learn More

Neglected Tropical Diseases

Learn More

Pioneering Investment Models for Drug Development Summit

Learn More

Top Five Reasons to Attend

  1. Engage in case studies and panel discussions on how to excel in searching for drug repurposing opportunities and uncover new indications for existing drugs
  2. Identify new technologies used for the evaluation of repurposed drugs
  3. Explore how to develop strategic partnerships between the government, universities, patient advocacy groups, foundations, and sponsors
  4. Cover new methods in the pipeline by using innovative strategies to discover new therapeutic uses for existing molecules
  5. Identify new indications of marketed drugs for rare and neglected diseases

Request More Information

More Information
live chat software